Immunocore to present at upcoming investor conferencesImmunocore to present at upcoming investor conferences
Immunocore presented two posters at CROI 2024Immunocore presented two posters at CROI 2024
Immunocore to present at upcoming investor conferencesImmunocore to present at upcoming investor conferences
Immunocore reports fourth quarter and full year 2023 financial results and provides a business updateImmunocore reports fourth quarter and full year 2023 financial results and provides a business update
Immunocore to report fourth quarter and full year 2023 financial results and host call on February 28, 2024Immunocore to report fourth quarter and full year 2023 financial results and host call on February 28, 2024
Immunocore Prices Upsized Convertible Senior Notes OfferingImmunocore Prices Upsized Convertible Senior Notes Offering
Immunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentationImmunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation
Immunocore to present at the 42nd Annual J.P. Morgan Healthcare ConferenceImmunocore to present at the 42nd Annual J.P. Morgan Healthcare Conference
Immunocore Reports Third Quarter 2023 Financial Results and Provides Business UpdateImmunocore Reports Third Quarter 2023 Financial Results and Provides Business Update
Immunocore announces upcoming poster presentations at SITC Annual Meeting 2023 and SMR Congress 2023(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md, 01 November 2023) Immunocore Holdings plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious diseases and autoimmune conditions, will present data for KIMMTRAK (tebentafusp-tebn) in metastatic uveal melanoma and cutaneous melanoma at the Society for Immunotherapy of Cancer's (SITC) Annual Meeting (1st – 5th November) and the Society for Melanoma Research (SMR) Congress (6th – 9th November).
Immunocore to present at upcoming investor conferencesImmunocore to present at upcoming investor conferences
Immunocore presents three-year overall survival data from the KIMMTRAK Phase 3 trialData published in New England Journal of Medicine and presented as a late breaking abstract in mini oral session at ESMO Congress 2023
Immunocore announces upcoming presentation and posters at ESMO 2023Immunocore announces upcoming presentation and posters at ESMO 2023
Immunocore to present at upcoming investor conferencesImmunocore to present at upcoming investor conferences
Immunocore to present at upcoming investor conferencesImmunocore to present at upcoming investor conferences
Immunocore to report second quarter 2023 financial results and host call on August 10, 2023Immunocore to report second quarter 2023 financial results and host call on August 10, 2023
Immunocore presents additional ctDNA data from the KIMMTRAK Phase 3 trial at ASCOEarly on-treatment ctDNA reduction in stable disease patients treated with KIMMTRAK was associated with longer overall survival
Immunocore to present at upcoming investor conferencesImmunocore to present at upcoming investor conferences
Immunocore Reports First Quarter 2023 Financial Results and Provides Business UpdateImmunocore Reports First Quarter 2023 Financial Results and Provides Business Update
Immunocore to present at the Bank of America Securities 2023 Health Care ConferenceImmunocore to present at the Bank of America Securities 2023 Health Care Conference
Immunocore presents new KIMMTRAK data confirming association between early ctDNA reduction and longer overall survivalImmunocore presents new KIMMTRAK data confirming association between early ctDNA reduction and longer overall survival
Immunocore to present at the 22nd Annual Needham Virtual Healthcare ConferenceImmunocore to present at the 22nd Annual Needham Virtual Healthcare Conference
Immunocore to present four posters at AACR Annual Meeting 2023Immunocore to present four posters at AACR Annual Meeting 2023
Immunocore Reports 2022 Financial Results and Provides Business UpdateImmunocore Reports 2022 Financial Results and Provides Business Update
Immunocore to present at upcoming investor conferencesImmunocore to present at upcoming investor conferences
Immunocore to Report Fourth Quarter and Full Year 2022 Earnings and Host Call on March 1, 2023Immunocore to Report Fourth Quarter and Full Year 2022 Earnings and Host Call on March 1, 2023
Immunocore announces initial Phase 1 safety and pharmacodynamic activity data with first soluble TCR therapy for people living with HIVImmunocore announces initial Phase 1 safety and pharmacodynamic activity data with first soluble TCR therapy for people living with HIV
Immunocore to present at upcoming investor conferencesImmunocore to present at upcoming investor conferences
Immunocore announces strategic priorities including pipeline expansion for 2023 -2024Immunocore announces strategic priorities including pipeline expansion for 2023 -2024
Immunocore to present at the 41st Annual J.P. Morgan Healthcare ConferenceImmunocore to present at the 41st Annual J.P. Morgan Healthcare Conference
Immunocore is awarded the Prix Galien France award for KIMMTRAKImmunocore is awarded the Prix Galien France award for KIMMTRAK
Immunocore presents ovarian cancer expansion data for ImmTAC® candidate IMC-C103C targeting MAGE-A4Immunocore presents ovarian cancer expansion data for ImmTAC® candidate IMC-C103C targeting MAGE-A4
Immunocore and Gadeta Announce Agreement to Develop First Gamma Delta (γδ) TCR ImmTAC for Solid TumorsImmunocore and Gadeta Announce Agreement to Develop First Gamma Delta (γδ) TCR ImmTAC for Solid Tumors
Immunocore to present at the 5th Annual Evercore ISI HealthCONx ConferenceImmunocore to present at the 5th Annual Evercore ISI HealthCONx Conference
Immunocore presents new biomarker analysis for KIMMTRAK (tebentafusp-tebn) in metastatic uveal melanoma at the SITC 2022 Annual MeetingImmunocore presents new biomarker analysis for KIMMTRAK (tebentafusp-tebn) in metastatic uveal melanoma at the SITC 2022 Annual Meeting
Immunocore to present at the Jefferies London Healthcare ConferenceImmunocore to present at the Jefferies London Healthcare Conference
